-
Cell publishes the functional pattern of basic genes! The function of more than 5,000 genes needed for human cells to survive
Time of Update: 2023-01-06
Using a novel, ensemble, image-based screening method, a team of scientists at the Whitehead Institute, the Massachusetts Institute of Technology and Harvard University's Broad Institute systematically assessed the function of more than 5,000 basic human genes.
-
Peng's lab published papers at CELLS
Time of Update: 2023-01-06
3390/cells11203290Published: OCT 2022Document type: ArticleAttachment: Full text link ：Unraveling Differential Transcriptomes and Cell Types in Zebrafish Larvae Intestine and Liver（IF=7.
3390/cells11203290Published: OCT 2022Document type: ArticleAttachment: Full text link ：Unraveling Differential Transcriptomes and Cell Types in Zebrafish Larvae Intestine and Liver（IF=7.
-
Peng's lab published papers at CELLS
Time of Update: 2023-01-06
3390/cells11203290Published: OCT 2022Document type: ArticleAttachment: Full text link ：Unraveling Differential Transcriptomes and Cell Types in Zebrafish Larvae Intestine and Liver（IF=7.
3390/cells11203290Published: OCT 2022Document type: ArticleAttachment: Full text link ：Unraveling Differential Transcriptomes and Cell Types in Zebrafish Larvae Intestine and Liver（IF=7.
-
Cell publishes the functional pattern of basic genes! The function of more than 5,000 genes needed for human cells to survive
Time of Update: 2023-01-06
Using a novel, ensemble, image-based screening method, a team of scientists at the Whitehead Institute, the Massachusetts Institute of Technology and Harvard University's Broad Institute systematically assessed the function of more than 5,000 basic human genes.
-
Astrocytes feed glioblastoma and promote tumor growth
Time of Update: 2022-10-12
In the new study, researchers at Tel Aviv University demonstrated that astrocytes do support glioma after its initial onset of pathogenesis, both by remodeling immune cells to support tumor growth and by providing the tumor with enough cholesterol to maintain its survival.
-
European Radiology: Evaluation of response to yttrium-90 radioembolization in hepatocellular carcinoma using MRI
Time of Update: 2022-10-10
Recently, a study published in the journal European Radiology evaluated the diagnostic performance of gadoxetate disodium-enhanced MRI in predicting complete pathological necrosis (CPN) in HCC after TARE therapy using histopathology as a reference standard, for accurate clinical evaluation of treatment.
-
The first time in the world! Science at ShanghaiTech University analyzes the first bitter taste receptor structure
Time of Update: 2022-10-03
On September 16th, the joint research team of Zhijie Liu and Huatian of ShanghaiTech University published a long research paper in the journal Science, which made a major original breakthrough in the structural basis research of strychnine activating the human bitter taste receptor TAS2R46, and unveiled the "mystery" of bitter taste receptor for the first time in the world.
-
Neurology Cases: Ganglion Cell Patterns Localize Anterior Visual Pathway Lesions
Time of Update: 2022-08-19
Video applet like, double-tap to cancel the like and watch, double-tap to cancel the view In the management of pituitary tumors compressing the optic chiasm, measurement of retinal ganglion cell layer thickness by optical coherence tomography provides an objective and reliable assessment of anterior visual pathway lesions to complement visual field examination .
-
Multi-pharmaceutical companies signed overseas licensing agreements to accelerate international market layout
Time of Update: 2022-05-24
On the morning of April 7, Harbin Pharmaceutical announced that it has entered into a global external licensing agreement with AstraZeneca to develop and commercialize HBM7022 .
-
During the development of innovative drugs, how does the sponsor communicate with CDE
Time of Update: 2022-04-28
. In 2013, the regulatory authorities issued the "Opinions of the State Food and Drug Administration on Deepening the Reform of Drug Review and Approval and Further Encouraging Drug Innovation", established a network electronic communication platform, and established an appointment-based communication mechanism to ensure that new drug R&D institutions and technical review departments are timely Communication, written records of communication results .
-
The next generation of antibody drugs - double antibodies: pharmaceutical companies are enthusiastic about research and development, and the competitive landscape is good
Time of Update: 2022-02-21
Recently, Kangfang Bio announced that its Phase Ib/II clinical trial application of AK104 combined with AK112 has been approved by China's CDE, with or without chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC) .
-
Could a genetic network similar to air traffic explain arteriosclerosis
Time of Update: 2022-01-23
Researchers at the Icahn School of Medicine at Mount Sinai have found that nearly 60 percent of the risk associated with coronary artery disease can be explained by the activity of multiple organ gene networks .
-
"If you pay, you will gain"-the innovative evolutionary history of Bolete species from brown rot to symbiosis
Time of Update: 2021-12-29
The research was funded by the Kunming Institute of Botany, Chinese Academy of Sciences Yang Zhu Liang research team and the French National Institute of Agriculture, Food and the Environment Nancy Center Francis Martin completion of teamwork, research has to "Evolutionary innovations through gain and loss of genes in the ectomycorrhizal Boletales" as The title was published online in the journal New Phytologist .
-
10 pharmaceutical companies are favored by capital, accelerating the development of innovative drugs
Time of Update: 2021-11-14
On November 1st, Anjisheng Bio, which focuses on the research and development of innovative drugs for bone, joint and muscle diseases, announced the completion of the B round of US$70 million in financing .
-
42 new drugs have been approved for clinical use, and dual-antibody drugs have exploded
Time of Update: 2021-09-19
This time, the product was approved for clinical use in China and is intended to be developed for advanced solid tumors .
This time, HMPL-453 was approved for clinical use in China, and the proposed development indications are: combined chemotherapy or anti-PD-1 monoclonal antibody for patients with advanced solid tumors .
